Healthy Males Clinical Trial
Official title:
The Influence of Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Passive Heat Stress
Increased core temperature (hyperthermia) has been associated with impaired neuromuscular
performance; however, the mechanisms associated with these performance decrements and their
potential synergies remain unclear. While the majority of research suggests that the observed
fatigue is related to the central nervous system, the influence of changes in cerebral blood
flow (CBF) and associated changes in cerebral alkalosis (estimated by end-tidal partial
pressure of carbon dioxide; PETCO2) remains unexamined. In response to hyperthermia, humans
hyperventilate as means of heat dissipation, resulting in a hypocapnia (reduced PETCO2)
mediated decrease in CBF and consequently, cerebral alkalosis (increased cerebral pH).
Previous research suggests that hyperventilation induces changes in neural excitability and
synaptic transmission; however, it remains unclear if these changes are related to hypocapnia
mediated decrease in CBF or decreased PETCO2 or both.
The purpose of the proposed research program is to examine the influence of changes in CBF
and cerebral alkalosis on neuromuscular function during passive heat stress. The research
project will consist of 3 separate experimental trials: (a) poikilocapnic hyperthermia
(increased core temperature; decrease CBF; decrease PETCO2), (b) isocapnic hyperthermia
(increased core temperature; no change CBF; no change PETCO2) and (c) isocapnic hyperthermia
+ indomethacin (increased core temperature; decrease CBF; no change PETCO2). During each
manipulation, neuromuscular function will be evaluated and compared to baseline
(normothermic) conditions using a repeated measures design.
It is hypothesized that changes in PETCO2 and therefore, changes in cerebral alkalosis will
contribute to neuromuscular fatigue independent of changes in CBF or increases in core
temperature.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04234594 -
Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.
|
Phase 1 | |
| Completed |
NCT01367561 -
Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function
|
Phase 1 | |
| Completed |
NCT00777543 -
Increasing Ferulic Acid Bioavailability in Bran
|
N/A | |
| Recruiting |
NCT04756635 -
Effects of Short- Term Intermittent Fasting Aerobic and Anaerobic Capacity
|
N/A | |
| Completed |
NCT02156661 -
Oxytocin and Emotion Processing
|
Phase 1 | |
| Completed |
NCT05294198 -
Beetroot Extract and Its Influence on Cardiovascular and Autonomic Recovery From the Effort in Healthy Males
|
N/A | |
| Completed |
NCT00839319 -
HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone
|
Phase 1/Phase 2 | |
| Completed |
NCT00842751 -
Oral T7 Oral Testosterone in Man
|
Phase 2 | |
| Completed |
NCT01847053 -
Bioavailability Study of Cinnamon in Healthy Subjects
|
Phase 1/Phase 2 | |
| Completed |
NCT01215292 -
ITT4 Intratesticular Hormonal Milieu in Man (ITT4)
|
Phase 1/Phase 2 | |
| Completed |
NCT00782392 -
Bioavailability and Dosing of a Monosaccharide Supplement in Adults
|
N/A | |
| Completed |
NCT03714685 -
Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations
|
Phase 1 | |
| Completed |
NCT05277597 -
Effect of a 4-week Post-exercise Sauna Bathing on Targeted Gut Microbiota
|
N/A | |
| Completed |
NCT01032616 -
Uptake and Utilization of Amino Acids by Splanchnic Bed
|
Phase 1 | |
| Completed |
NCT01830335 -
Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Environmental Stress
|
Phase 4 | |
| Completed |
NCT00902512 -
Study Of Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations
|
Phase 4 | |
| Completed |
NCT00475371 -
A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males
|
Phase 1 | |
| Completed |
NCT01870102 -
Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects
|
Phase 1 |